RecruitingPhase 4NCT07111247

Insights in Endocervical Mucus Secretion

Sponsor

Oregon Health and Science University

Enrollment

15 participants

Start Date

Jan 2, 2026

Study Type

INTERVENTIONAL

Conditions

Cervical Mucus

Summary

Single arm interventional study looking at biological outcomes at 4 time points throughout the cycle before and after taking an oral gonadotropin-releasing hormone antagonist (gnRH). Samples of whole blood, endocervical mucus, endocervical biopsy, and vaginal swab will be collected.

Eligibility

Sex: FEMALEMin Age: 21 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Gonadotropin Releasing Hormone Antagonists Relugolix for people with cervical mucus. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 21 Years to 40 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGonadotropin Releasing Hormone Antagonists Relugolix

Gonadotropin releasing hormone antagonist (gnRH) taken for 10 days starting during the midluteal phase.

Locations(1)

Oregon Health & Science University

Portland, Oregon, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07111247

Related Trials

Smartphone vs Manual Interpretation of Biomarkers for Ovulation and Luteal Phase Detection (SMOM Study)

NCT072480461 location